君實生物(01877.HK)重組人源化抗IL-17A單克隆抗體注射液完成首例患者給藥
君實生物(01877.HK)公布,重組人源化抗IL-17A單克隆抗體注射液(項目代號JS005)在中國開展的I期臨床研究NCT04220073已完成首例患者給藥。該研究旨在評價JS005單次給藥在健康志願者中的耐受性、安全性、藥代動力學(PK)特徵和免疫原性。
IL-17A是一種具有多效性的細胞因子,其分泌失調與自身免疫性疾病如銀屑病、類風濕關節炎、強直性脊柱炎等疾病的發生發展密切相關。JS005通過與IL-17A高親和力結合併選擇性地阻斷IL-17A與其受體IL-17RA/IL-17RC的結合,從而阻斷下游信號通路的啟動和炎性因子的釋放,緩解疾病症狀。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.